Sitemap > Breaking Research > Infectious Diseases
Displaying 701 - 750 of 4290 results
- CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection.
- Photothermal nanotherapeutics and nanodiagnostics for selective killing of bacteria targeted with gold nanoparticles.
- Immunological control of tuberculosis: role of tumour necrosis factor and more.
- Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.
- Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.
- Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
- High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.
- TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
- A class of pantothenic acid analogs inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of malaria parasites.
- Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections.
- Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.
- Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
- Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection.
- Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.
- Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.
- In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
- Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.
- The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
- A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats.
- Inhibition of DNA helicases with DNA-competitive inhibitors.
- Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.
- A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
- Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
- Design, synthesis, and microbiological evaluation of new Candida albicans CYP51 inhibitors.
- Structure of a synthetic fragment of the lipopolysaccharide (LPS) binding protein when bound to LPS and design of a peptidic LPS inhibitor.
- Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
- Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-{1-[(pyridine-4-carbonyl)hydrazono]ethyl}phenyl)thiourea.
- Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones.
- Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
- Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
- Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.
- Structure-guided discovery of novel aminoglycoside mimetics as antibacterial translation inhibitors.
- Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
- High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery.
- In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
- Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.
- A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.
- Human immunodeficiency virus type 1 latency model for high-throughput screening.
- Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter.
- Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
- Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.
- Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response.
- Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6.
- Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.
- CD4+ T cell-independent DNA vaccination against opportunistic infections.
- Carbon monoxide increases macrophage bacterial clearance through Toll-like receptor (TLR)4 expression.
- Synthesis of some novel pyrazolo[3,4-d]pyrimidine derivatives as potential antimicrobial agents.
- A role for LEDGF/p75 in targeting HIV DNA integration.
- Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
- Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >